Danaher Corporation reported strong second-quarter 2025 results, with sales reaching $5.936 billion, a 3.5% increase year-over-year, surpassing the consensus estimate of $5.84 billion. Non-GAAP core revenue grew by 1.5% year-over-year, exceeding expectations for low-single-digit growth.
Adjusted earnings per share (EPS) for the quarter were $1.80, beating the consensus estimate of $1.64. This performance was driven by robust growth in the bioprocessing business and disciplined cost management, despite a significant $432 million impairment charge related to an indefinite-lived trade name in the Life Sciences segment.
Danaher increased its full-year adjusted diluted net EPS guidance to a range of $7.70 to $7.80, up from previous guidance of $7.60 to $7.75. For the third quarter of 2025, the company anticipates non-GAAP core revenue to grow in the low-single-digit percent range, maintaining its full-year core revenue growth expectation of approximately 3%.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.